Global Health

Our approach to social impact starts with our medicines and our commitment to expand access to those medicines to as many people as possible. We extend our reach by being part of the solution for complex global health challenges that disproportionately affect people living in settings with limited resources.

We expand our impact even further by working to strengthen communities around the world. We invest our resources, time and expertise to drive social impact, with a focus on improving health and education. We encourage and support our employees’ efforts to give and volunteer in ways that help make life better.

Reaching Children with Diabetes

Since 2009, Lilly has donated more than 8.1 million vials and cartridges of insulin through Life for a Child

Improving Screening for Breast and Cervical Cancer in Kenya

As of 2024, approximately 200,000 people have been screened for breast and cervical cancer in Kenya through AMPATH with the support of the Lilly Foundation and other partners. Community health screening has enabled people like Nancy Odari to receive early diagnosis and treatment.

Employee Volunteering

Lilly’s Global Day of Service is one of the largest single day volunteer programmes in the world. Our employees have volunteered in 65 countries and given more than 1 million hours since 2008.

Disaster Relief

Disasters bring chaos and can change lives in an instant. That's why Lilly works with leading disaster relief organisations to prepare for the worst and respond with our collective best. We do this through disaster readiness efforts, providing medicines when requested by our partners and supporting people and communities to help them recover.

Lilly 30x30

Globally, we’ve established an aggressive goal – Lilly 30x30 – to improve access to quality healthcare for 30 million people, each year, by 2030. We focus on people living in communities with limited resources, including those who might not be reached by Lilly’s traditional business model.

Reaching our 30x30 goal will take far more than philanthropy. It requires a stronger mix of creative approaches across our business and with our partners that help expand access for more people.

We focus our 30x30 effort in three key areas:

• Pipeline: Discovering medicines and repurposing internal assets and legacy products for diseases that disproportionately affect people in resource-limited settings. 

• Programmes: Strengthening and creating new programmes that help improve access to Lilly medicines.

• Partnerships: Building partnerships that strengthen health systems, increase access to medicines and improve care.